Skip to main content
Clinical Trials/NCT06051708
NCT06051708
Completed
Not Applicable

Risk Factors And Outcomes Of Hospital Acquired Acute Kidney Injury: A Tertiary Health Care Center Experience

Alexandria University1 site in 1 country160 target enrollmentJune 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
AKI - Acute Kidney Injury
Sponsor
Alexandria University
Enrollment
160
Locations
1
Primary Endpoint
Recovery of kidney functions
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim of the study is to assess the common risk factors for development of hospital acquired acute kidney injury among hospitalized patients in Alexandria Main University hospital and their outcomes.

Detailed Description

Hospital-acquired AKI (HAAKI) is defined as acute renal insult occurring 48 hours or more after admission to a health care facility and It is estimated to occur in 13-18% of hospitalized patients. The early diagnosis of HAAKI reflects on improvement in morbidity and mortality rates especially in developing countries which goes parallel with the goal The International Society of Nephrology (ISN) to eliminate preventable or treatable deaths from AKI by 2025, the "0 by 25" initiative. Data concerning the spectrum of acute kidney injury (AKI) in Egypt are generally scarce.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
May 15, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohamed Mamdouh Mahmoud Mohamed Elsayed , MD

Lecturer

Alexandria University

Eligibility Criteria

Inclusion Criteria

  • Fulfilment of definition of acute kidney injury according to KDIGO reference.
  • Age more than 18 years.

Exclusion Criteria

  • Mentally or physically unfit patients.
  • Patients who developed acute kidney injury within 48 hours of admission to hospital.

Outcomes

Primary Outcomes

Recovery of kidney functions

Time Frame: 12 weeks

(improvement of eGFR, serum creatinine to normal or previous baseline).

Secondary Outcomes

  • Need for renal replacement therapy(12 weeks)
  • mortality(12 weeks)
  • progression to chronic kidney disease.(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials